$Affimed(AFMD)$ 数据不错,盘前涨了一些。

Affimed Announces Presentation at AACR Hi ghlighting Initial Data from Phase 1 St udy of Cord Blood-derived Natural Killer Cells Pre-complexed with Innate Cell Engager AFM13

All four patients experienced significant disease reduction, with two complete responses and two partial responses as assessed by the investigator, with an objective response rate of 100%

There were no observed events of cytokine release syndrome, neurotoxicity syndrome or graft-versus-host disease

Study is continuing enrollment of the second dose cohort

$Fate Therapeutics(FATE)$ $Moderna(MRNA)$



JBTFD04-09 20:47